Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 3/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3618781 | 1.00 | TDO2 (0.38) | TDO2CHRNA7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL3613503 | 0.87 | TDO2 (0.38) | TDO2CHRNA7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL3613500 | 0.87 | TDO2 (0.38) | TDO2CHRNA7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL3622393 | 0.87 | GRM5 (0.35) | CHRNA7GRM5HCRTR2HCRTR1 | |
| SCHEMBL3622392 | 0.87 | GRM5 (0.35) | CHRNA7GRM5HCRTR2HCRTR1 | |
| SCHEMBL3616337 | 0.86 | FAAH (0.43) | TDO2CHRNA7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL3616333 | 0.86 | FAAH (0.43) | TDO2CHRNA7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL3608094 | 0.84 | CHRNA7 (0.41) | TDO2CHRNA7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL3608098 | 0.84 | CHRNA7 (0.41) | TDO2CHRNA7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL3617444 | 0.82 | CHRNB2 (0.42) | TDO2CHRNA7CHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657010-B2 | Substituted quinuclidines as alpha 7-nicotinic acetylcholine receptor activity modulators | NOVARTIS AG (CH) | 2017-05-23 | — | — | US | disclosed |
| US-20140057921-A1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA. 7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES | NOVARTIS AG (CH) | 2014-02-27 | — | — | US | disclosed |
| US-8609662-B2 | 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha. 7-nachr ligands for the treatment of CNS diseases | NOVARTIS AG (CH) | 2013-12-17 | — | — | US | disclosed |
| EP-2457911-A1 | 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha.7-nAChR ligands for the treatment of CNS diseases. | Novartis AG (CH) | 2012-05-30 | — | — | EP | disclosed |
| US-20100093746-A1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA. 7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES | NOVARTIS AG | 2010-04-15 | — | — | US | disclosed |
| US-20080194573-A1 | Psychological and neurodegenerative disorders; nicotinic acetylcholine receptors | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1776360-A1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA.7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES. | Novartis AG (CH) | 2007-04-25 | — | — | EP | disclosed |
| WO-2006005608-A1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA.7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES | NOVARTIS AG (CH) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194573-A1 | Psychological and neurodegenerative disorders; nicotinic acetylcholine receptors | CHRNA7, CHRNA5, CHRNA6 | TDO2 3744/4885CHRNA7 1/4885CHRNB2 11/4885 |
| US-20100093746-A1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA. 7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES | CHRNA7, CHRNA5, CHRNA2 | TDO2 2660/4885CHRNA7 1/4885CHRNB2 11/4885 |
| US-20140057921-A1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA. 7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES | CHRNA7, CHRNA5, CHRNA2 | TDO2 2660/4885CHRNA7 1/4885CHRNB2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.